

al. (American Journal of Pathology, Vol. 181, No. 6, December 2012), Henry, et al. (Oncotarget, Vol. 6, No. 37 2015), Zhang, et al. (PLoS ONE 7(3): e31127.), and Bainbridge, et al. (PLoS ONE 9(7): e102695.), each herein incorporated by reference in their entirety. In addition, ROR expression may not be expressed, or only demonstrate limited expression, in normal, i.e. non-cancerous, tissue as described in Balakrishnan et al. (Clin Cancer Res. 2017 Jun 15; 23(12): 3061–3071), herein incorporated in its entirety. Thus ROR antigens can be used as a tumor-specific marker in certain tumors. Examples of tumors and cancers with demonstrated ROR expression include, but are not limited to, pancreatic cancer, ovarian cancer, breast cancer, lung cancer, gastric cancer, melanoma, Ewing sarcoma, chronic lymphocytic leukemia, mantle cell lymphoma, and B-ALL, as described in Gohil et al. (Oncoimmunology. 2017; 6(7): e1326437.), herein incorporated in its entirety. Other cancers include, but are not limited to, hematological cancer, prostate cancer, colon cancer, renal cancer, and uterine cancer. Use of ROR multispecific antibodies, formatted in various antibody platforms, to target tumors is described in Gohil, et al., international application WO 2017/053469, international application WO 2014/167022, U.S. Pub. No. 2017/0198045, international application WO 2016/094873, international application WO 2017/127499, and international application WO 2016/142768, each of which is herein incorporated by reference in its entirety.

[0006] ROR antigen binding molecules thus have therapeutic potential in treatment of cancer. Multispecific ROR binding molecules that bind T cell surface antigens in addition to a ROR antigen have potential to provide T cell redirected killing of ROR-expressing cancer cells.

[0007] There is, therefore, a need for ROR antigen binding molecules, including multispecific ROR antigen binding molecules. There is also a need for ROR antigen binding molecules that have improvements including increased affinity or avidity, reduced off-target binding, and/or reduced unintended immune activation. There is a particular need for a multispecific ROR antigen binding molecule that has improved manufacturability, and is readily purified.

4. SUMMARY

[0008] In one aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody heavy chain variable (VH) region, and an antibody light chain variable (VL) region,

wherein the antigen binding site comprises all three VH region complementarity determining regions (CDRs) and all three VL region CDRs from the antibody designed I2A-1, and wherein the VH CDR1 comprises SEQ ID NO: 153, the VH CDR2 comprises SEQ ID NO: 154, the VH CDR3 comprises SEQ ID NO: 155, the VL CDR1 comprises SEQ ID NO: 156, the VL CDR2 comprises SEQ ID NO: 157, and the VL CDR3 comprises SEQ ID NO: 158, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008a] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-3, and wherein the VH CDR1 comprises SEQ ID NO: 165, the VH CDR2 comprises SEQ ID NO: 166, the VH CDR3 comprises SEQ ID NO: 167, the VL CDR1 comprises SEQ ID NO: 168, the VL CDR2 comprises SEQ ID NO: 169, and the VL CDR3 comprises SEQ ID NO: 170, wherein the antigen binding site is specific for ROR1.

[0008b] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-4, and wherein the VH CDR1 comprises SEQ ID NO: 171, the VH CDR2 comprises SEQ ID NO: 172, the VH CDR3 comprises SEQ ID NO: 173, the VL CDR1 comprises SEQ ID NO: 174, the VL CDR2 comprises SEQ ID NO: 175, and the VL CDR3 comprises SEQ ID NO: 176, wherein the antigen binding site is specific for ROR1.

[0008c] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-6, and wherein the VH CDR1 comprises SEQ ID NO: 183, the VH CDR2 comprises SEQ ID NO: 184, the VH CDR3 comprises SEQ ID NO: 185, the VL CDR1 comprises SEQ ID NO: 186, the VL CDR2 comprises SEQ ID NO: 187, and the VL CDR3 comprises SEQ ID NO: 188, wherein the antigen binding site is specific for ROR1.

[0008d] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-8, and wherein the VH CDR1 comprises SEQ ID NO: 195, the VH CDR2 comprises SEQ ID NO: 196, the VH CDR3 comprises SEQ ID NO: 197, the VL CDR1 comprises SEQ ID NO: 198, the VL CDR2 comprises SEQ ID NO: 199, and the VL CDR3 comprises SEQ ID NO: 200, wherein the antigen binding site is specific for ROR1.

[0008e] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-11, and wherein the VH CDR1 comprises SEQ ID NO: 219, the VH CDR2 comprises SEQ ID NO: 220, the VH CDR3 comprises SEQ ID NO: 221, the VL CDR1 comprises SEQ ID NO: 222, the VL CDR2 comprises SEQ ID NO: 223, and the VL CDR3 comprises SEQ ID NO: 224, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008f] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-12, and wherein the VH CDR1 comprises SEQ ID NO: 225, the VH CDR2 comprises SEQ ID NO: 226, the VH CDR3 comprises SEQ ID NO: 227, the VL CDR1 comprises SEQ ID NO: 228, the VL CDR2 comprises SEQ ID NO: 229, and the VL CDR3 comprises SEQ ID NO: 230, wherein the antigen binding site is specific for ROR1.

[0008g] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-13, and wherein the VH CDR1 comprises SEQ ID NO: 231, the VH CDR2 comprises SEQ ID NO: 232, the VH CDR3 comprises SEQ ID NO: 233, the VL CDR1 comprises SEQ ID NO: 234, the VL CDR2 comprises SEQ ID NO: 235, and the VL CDR3 comprises SEQ ID NO: 236, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008h] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-14, and wherein the VH CDR1 comprises SEQ ID NO: 237, the VH CDR2 comprises SEQ ID NO: 238, the VH CDR3 comprises SEQ ID NO: 239, the VL CDR1 comprises SEQ ID NO: 240, the VL CDR2 comprises SEQ ID NO: 241, and the VL CDR3 comprises SEQ ID NO: 242, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008i] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-16, and wherein the VH CDR1 comprises SEQ ID NO: 249, the VH CDR2 comprises SEQ ID NO: 250, the VH CDR3 comprises SEQ ID NO: 251, the VL CDR1 comprises SEQ ID NO: 252, the VL CDR2 comprises SEQ ID NO: 253, and the VL CDR3 comprises SEQ ID NO: 254, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008j] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-18, and wherein the VH CDR1 comprises SEQ ID NO: 261, the VH CDR2 comprises SEQ ID NO: 262, the VH CDR3 comprises SEQ ID NO: 263, the VL CDR1 comprises SEQ ID NO: 264, and the VL CDR2 comprises SEQ ID NO: 265, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008k] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-19, and wherein the VH CDR1 comprises SEQ ID NO: 266, the VH CDR2 comprises SEQ ID NO: 267, the VH CDR3 comprises SEQ ID NO: 268, the VL CDR1 comprises SEQ ID NO: 269, the VL CDR2 comprises SEQ ID NO: 270, and the VL CDR3 comprises SEQ ID NO: 271, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008l] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-20, and wherein the VH CDR1 comprises SEQ ID NO: 272, the VH CDR2 comprises SEQ ID NO: 273, the VH CDR3 comprises SEQ ID NO: 274, the VL CDR1 comprises SEQ ID NO: 275, the VL CDR2 comprises SEQ ID NO: 276, and the VL CDR3 comprises SEQ ID NO: 277, wherein the antigen binding site is specific for ROR1.

[0008m] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-22, and wherein the VH CDR1 comprises SEQ ID NO: 284, the VH CDR2 comprises SEQ ID NO: 285, the VH CDR3 comprises SEQ ID NO: 286, the VL CDR1 comprises SEQ ID NO: 287, the VL CDR2 comprises SEQ ID NO: 288, and the VL CDR3 comprises SEQ ID NO: 289, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008n] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-24, and wherein the VH CDR1 comprises SEQ ID NO: 296, the VH CDR2 comprises SEQ ID NO: 297, the VH CDR3 comprises SEQ ID NO: 298, the VL CDR1 comprises SEQ ID NO: 299, the VL CDR2 comprises SEQ ID NO: 300, and the VL CDR3 comprises SEQ ID NO: 301, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008o] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-25, and wherein the VH CDR1 comprises SEQ ID NO: 302, the VH CDR2 comprises SEQ ID NO: 303, the VH CDR3 comprises SEQ ID NO: 304, the VL CDR1 comprises SEQ ID NO: 305, the VL CDR2 comprises SEQ ID NO: 306, and the VL CDR3 comprises SEQ ID NO: 307, wherein the antigen binding site is specific for ROR1.

[0008p] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-26, and wherein the VH CDR1 comprises SEQ ID NO: 308, the VH CDR2 comprises SEQ ID NO: 309, the VH CDR3 comprises SEQ ID NO: 310, the VL CDR1 comprises SEQ ID NO: 311, the VL CDR2 comprises SEQ ID NO: 312, and the VL CDR3 comprises SEQ ID NO: 313, wherein the antigen binding site is specific for ROR1.

[0008q] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-30, and wherein the VH CDR1 comprises SEQ ID NO: 332, the VH CDR2 comprises SEQ ID NO: 333, the VH CDR3 comprises SEQ ID NO: 334, the VL CDR1 comprises SEQ ID NO: 335, the VL CDR2 comprises SEQ ID NO: 336, and the VL CDR3 comprises SEQ ID NO: 337, wherein the antigen binding site is specific for ROR1.

[0008r] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-32, and wherein the VH CDR1 comprises SEQ ID NO: 344, the VH CDR2 comprises SEQ ID NO: 345, the VH CDR3 comprises SEQ ID NO: 346, the VL CDR1 comprises SEQ ID NO: 347, the VL CDR2 comprises SEQ ID NO: 348, and the VL CDR3 comprises SEQ ID NO: 349, wherein the antigen binding site is specific for ROR1.

[0008s] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-33, and wherein the VH CDR1 comprises SEQ ID NO: 350, the VH CDR2 comprises SEQ ID NO: 351, the VH CDR3 comprises SEQ ID NO: 352, the VL CDR1 comprises SEQ ID NO: 353, the VL CDR2 comprises SEQ ID NO: 354, and the VL CDR3 comprises SEQ ID NO: 355, wherein the antigen binding site is specific for ROR1.

[0008t] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-34, and wherein the VH CDR1 comprises SEQ ID NO: 356, the VH CDR2 comprises SEQ ID NO: 357, the VH CDR3 comprises SEQ ID NO: 358, the VL CDR1 comprises SEQ ID NO: 359, the VL CDR2 comprises SEQ ID NO: 360, and the VL CDR3 comprises SEQ ID NO: 361, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008u] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-36, and wherein the VH CDR1 comprises SEQ ID NO: 368, the VH CDR2 comprises SEQ ID NO: 369, the VH CDR3 comprises SEQ ID NO: 370, the VL CDR1 comprises SEQ ID NO: 371, the VL CDR2 comprises SEQ ID NO: 372, and the VL CDR3 comprises SEQ ID NO: 373, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008v] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-37, and wherein the VH CDR1 comprises SEQ ID NO: 374, the VH CDR2 comprises SEQ ID NO: 375, the VH CDR3 comprises SEQ ID NO: 376, the VL CDR1 comprises SEQ ID NO: 377, the VL CDR2 comprises SEQ ID NO: 378, and the VL CDR3 comprises SEQ ID NO: 379, wherein the antigen binding site is specific for ROR1.

[0008w] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-1, and wherein the VH CDR1 comprises SEQ ID NO: 385, the VH CDR2 comprises SEQ ID NO: 386, the VH CDR3 comprises SEQ ID NO: 387, the VL CDR1 comprises SEQ ID NO: 388, the VL CDR2 comprises SEQ ID NO: 389, and the VL CDR3 comprises SEQ ID NO: 390, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008x] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-2, and wherein the VH CDR1 comprises SEQ ID NO: 391, the VH CDR2 comprises SEQ ID NO: 392, the VH CDR3 comprises SEQ ID NO: 393, the VL CDR1 comprises SEQ ID NO: 394, the VL CDR2 comprises SEQ ID NO: 395, and the VL CDR3 comprises SEQ ID NO: 396, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008y] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-3, and wherein the VH CDR1 comprises SEQ ID NO: 397, the VH CDR2 comprises SEQ ID NO: 398, the VH CDR3 comprises SEQ ID NO: 399, the VL CDR1 comprises SEQ ID NO: 400, the VL CDR2 comprises SEQ ID NO: 401, and the VL CDR3 comprises SEQ ID NO: 402, wherein the antigen binding site is specific for ROR2.

[0008z] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-4, and wherein the VH CDR1 comprises SEQ ID NO: 403, the VH CDR2 comprises SEQ ID NO: 404, the VH CDR3 comprises SEQ ID NO: 405, the VL CDR1 comprises SEQ ID NO: 406, the VL CDR2 comprises SEQ ID NO: 407, and the VL CDR3 comprises SEQ ID NO: 408, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008aa] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-5, and wherein the VH CDR1 comprises SEQ ID NO: 409, the VH CDR2 comprises SEQ ID NO: 410, the VH CDR3 comprises SEQ ID NO: 411, the VL CDR1 comprises SEQ ID NO: 412, the VL CDR2 comprises SEQ ID NO: 413, and the VL CDR3 comprises SEQ ID NO: 414, wherein the antigen binding site is specific for ROR2.

[0008bb] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-6, and wherein the VH CDR1 comprises SEQ ID NO: 415, the VH CDR2 comprises SEQ ID NO: 416, the VH CDR3 comprises SEQ ID NO: 417, the VL CDR1 comprises SEQ ID NO: 418, the VL CDR2 comprises SEQ ID NO: 419, and the VL CDR3 comprises SEQ ID NO: 420, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008cc] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-7, and wherein the VH CDR1 comprises SEQ ID NO: 421, the VH CDR2 comprises SEQ ID NO: 422, the VH CDR3 comprises SEQ ID NO: 423, the VL CDR1 comprises SEQ ID NO: 424, the VL CDR2 comprises SEQ ID NO: 425, and the VL CDR3 comprises SEQ ID NO: 426, wherein the antigen binding site is specific for ROR2.

[0008dd] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-8, and wherein the VH CDR1 comprises SEQ ID NO: 427, the VH CDR2 comprises SEQ ID NO: 428, the VH CDR3 comprises SEQ ID NO: 429, the VL CDR1 comprises SEQ ID NO: 430, the VL CDR2 comprises SEQ ID NO: 431, and the VL CDR3 comprises SEQ ID NO: 432, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008ee] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-9, and wherein the VH CDR1 comprises SEQ ID NO: 433, the VH CDR2 comprises SEQ ID NO: 434, the VH CDR3 comprises SEQ ID NO: 435, the VL CDR1 comprises SEQ ID NO: 436, the VL CDR2 comprises SEQ ID NO: 437, and the VL CDR3 comprises SEQ ID NO: 438, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008ff] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-10, and wherein the VH CDR1 comprises SEQ ID NO: 439, the VH CDR2 comprises SEQ ID NO: 440, the VH CDR3 comprises SEQ ID NO: 441, the VL CDR1 comprises SEQ ID NO: 442, the VL CDR2 comprises SEQ ID NO: 443, and the VL CDR3 comprises SEQ ID NO: 444, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008gg] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-11, and wherein the VH CDR1 comprises SEQ ID NO: 445, the VH CDR2 comprises SEQ ID NO: 446, the VH CDR3 comprises SEQ ID NO: 447, the VL CDR1 comprises SEQ ID NO: 448, the VL CDR2 comprises SEQ ID NO: 449, and the VL CDR3 comprises SEQ ID NO: 450, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008hh] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-12, and wherein the VH CDR1 comprises SEQ ID NO: 451, the VH CDR2 comprises SEQ ID NO: 452, the VH CDR3 comprises SEQ ID NO: 453, the VL CDR1 comprises SEQ ID NO: 454, the VL CDR2 comprises SEQ ID NO: 455, and the VL CDR3 comprises SEQ ID NO: 456, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008ii] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-13, and wherein the VH CDR1 comprises SEQ ID NO: 457, the VH CDR2 comprises SEQ ID NO: 458, the VH CDR3 comprises SEQ ID NO: 459, the VL CDR1 comprises SEQ ID NO: 460, the VL CDR2 comprises SEQ ID NO: 461, and the VL CDR3 comprises SEQ ID NO: 462, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008jj] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-14, and wherein the VH CDR1 comprises SEQ ID NO: 463, the VH CDR2 comprises SEQ ID NO: 464, the VH CDR3 comprises SEQ ID NO: 465, the VL CDR1 comprises SEQ ID NO: 466, the VL CDR2 comprises SEQ ID NO: 467, and the VL CDR3 comprises SEQ ID NO: 468, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008kk] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-15, and wherein the VH CDR1 comprises SEQ ID NO: 469, the VH CDR2 comprises SEQ ID NO: 470, the VH CDR3 comprises SEQ ID NO: 471, the VL CDR1 comprises SEQ ID NO: 472, the VL CDR2 comprises SEQ ID NO: 473, and the VL CDR3 comprises SEQ ID NO: 474, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008ll] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-16, and wherein the VH CDR1 comprises SEQ ID NO: 475, the VH CDR2 comprises SEQ ID NO: 476, the VH CDR3 comprises SEQ ID NO: 477, the VL CDR1 comprises SEQ ID NO: 478, the VL CDR2 comprises SEQ ID NO: 479, and the VL CDR3 comprises SEQ ID NO: 480, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008mm] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-17, and wherein the VH CDR1 comprises SEQ ID NO: 481, the VH CDR2 comprises SEQ ID NO: 482, the VH CDR3 comprises SEQ ID NO: 483, the VL CDR1 comprises SEQ ID NO: 484, the VL CDR2 comprises SEQ ID NO: 485, and the VL CDR3 comprises SEQ ID NO: 486, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008nn] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-18, and wherein the VH CDR1 comprises SEQ ID NO: 487, the VH CDR2 comprises SEQ ID NO: 488, the VH CDR3 comprises SEQ ID NO: 489, the VL CDR1 comprises SEQ ID NO: 490, the VL CDR2 comprises SEQ ID NO: 491, and the VL CDR3 comprises SEQ ID NO: 492, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008oo] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-19, and wherein the VH CDR1 comprises SEQ ID NO: 493, the VH CDR2 comprises SEQ ID NO: 494, the VH CDR3 comprises SEQ ID NO: 495, the VL CDR1 comprises SEQ ID NO: 496, the VL CDR2 comprises SEQ ID NO: 497, and the VL CDR3 comprises SEQ ID NO: 498, wherein the antigen binding site is specific for ROR2.

[0008pp] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-20, and wherein the VH CDR1 comprises SEQ ID NO: 499, the VH CDR2 comprises SEQ ID NO: 500, the VH CDR3 comprises SEQ ID NO: 501, the VL CDR1 comprises SEQ ID NO: 502, the VL CDR2 comprises SEQ ID NO: 503, and the VL CDR3 comprises SEQ ID NO: 504, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008qq] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-21, and wherein the VH CDR1 comprises SEQ ID NO: 505, the VH CDR2 comprises SEQ ID NO: 506, the VH CDR3 comprises SEQ ID NO: 507, the VL CDR1 comprises SEQ ID NO: 508, the VL CDR2 comprises SEQ ID NO: 509, and the VL CDR3 comprises SEQ ID NO: 510, wherein the antigen binding site is specific for ROR2.

[0008rr] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-22, and wherein the VH CDR1 comprises SEQ ID NO: 511, the VH CDR2 comprises SEQ ID NO: 512, the VH CDR3 comprises SEQ ID NO: 513, the VL CDR1 comprises SEQ ID NO: 514, the VL CDR2 comprises SEQ ID NO: 515, and the VL CDR3 comprises SEQ ID NO: 516, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008ss] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-23, and wherein the VH CDR1 comprises SEQ ID NO: 517, the VH CDR2 comprises SEQ ID NO: 518, the VH CDR3 comprises SEQ ID NO: 519, the VL CDR1 comprises SEQ ID NO: 520, the VL CDR2 comprises SEQ ID NO: 521, and the VL CDR3 comprises SEQ ID NO: 522, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008tt] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-24, and wherein the VH CDR1 comprises SEQ ID NO: 523, the VH CDR2 comprises SEQ ID NO: 524, the VH CDR3 comprises SEQ ID NO: 525, the VL CDR1 comprises SEQ ID NO: 526, the VL CDR2 comprises SEQ ID NO: 527, and the VL CDR3 comprises SEQ ID NO: 528, wherein the antigen binding site is specific for ROR1 and ROR2.

[0008uu] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-25, and wherein the VH CDR1 comprises SEQ ID NO: 529, the VH CDR2 comprises SEQ ID NO: 530, the VH CDR3 comprises SEQ ID NO: 531, the VL CDR1 comprises SEQ ID NO: 532, the VL CDR2 comprises SEQ ID NO: 533, and the VL CDR3 comprises SEQ ID NO: 534, wherein the antigen binding site is specific for ROR2.

[0008vv] In another aspect, the present disclosure provides a tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising: an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-26, and wherein the VH CDR1 comprises SEQ ID NO: 535, the VH CDR2 comprises SEQ ID NO: 536, the VH CDR3 comprises SEQ ID NO: 537, the VL CDR1 comprises SEQ ID NO: 538, the VL CDR2 comprises SEQ ID NO: 539, and the VL CDR3 comprises SEQ ID NO: 540, wherein the antigen binding site is specific for ROR2.

[0008ww] In a first example, antigen binding molecules are provided. In every example, the antigen binding molecule includes at least an antigen binding site specific for a ROR antigen; the binding molecules are therefore termed ROR antigen binding molecules.

WHAT IS CLAIMED IS:

1. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody heavy chain variable (VH) region, and an antibody light chain variable (VL) region, wherein the antigen binding site comprises all three VH region complementarity determining regions (CDRs) and all three VL region CDRs from the antibody designed I2A-1, and wherein

the VH CDR1 comprises SEQ ID NO: 153,

the VH CDR2 comprises SEQ ID NO: 154,

the VH CDR3 comprises SEQ ID NO: 155,

the VL CDR1 comprises SEQ ID NO: 156,

the VL CDR2 comprises SEQ ID NO: 157, and

the VL CDR3 comprises SEQ ID NO: 158,

wherein the antigen binding site is specific for ROR1 and ROR2.

2. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-3, and wherein

the VH CDR1 comprises SEQ ID NO: 165,

the VH CDR2 comprises SEQ ID NO: 166,

the VH CDR3 comprises SEQ ID NO: 167,

the VL CDR1 comprises SEQ ID NO: 168,

the VL CDR2 comprises SEQ ID NO: 169, and

the VL CDR3 comprises SEQ ID NO: 170,

wherein the antigen binding site is specific for ROR1.

3. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-4, and wherein

the VH CDR1 comprises SEQ ID NO: 171,

the VH CDR2 comprises SEQ ID NO: 172,

the VH CDR3 comprises SEQ ID NO: 173,

the VL CDR1 comprises SEQ ID NO: 174,

the VL CDR2 comprises SEQ ID NO: 175, and

the VL CDR3 comprises SEQ ID NO: 176,

wherein the antigen binding site is specific for ROR1.

4. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding

site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-6, and wherein

the VH CDR1 comprises SEQ ID NO: 183,

the VH CDR2 comprises SEQ ID NO: 184,

the VH CDR3 comprises SEQ ID NO: 185,

the VL CDR1 comprises SEQ ID NO: 186,

the VL CDR2 comprises SEQ ID NO: 187, and

the VL CDR3 comprises SEQ ID NO: 188,

wherein the antigen binding site is specific for ROR1.

5. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-8, and wherein

the VH CDR1 comprises SEQ ID NO: 195,

the VH CDR2 comprises SEQ ID NO: 196,

the VH CDR3 comprises SEQ ID NO: 197,

the VL CDR1 comprises SEQ ID NO: 198,

the VL CDR2 comprises SEQ ID NO: 199, and

the VL CDR3 comprises SEQ ID NO: 200,

wherein the antigen binding site is specific for ROR1.

6. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-11, and wherein

the VH CDR1 comprises SEQ ID NO: 219,

the VH CDR2 comprises SEQ ID NO: 220,

the VH CDR3 comprises SEQ ID NO: 221,

the VL CDR1 comprises SEQ ID NO: 222,

the VL CDR2 comprises SEQ ID NO: 223, and

the VL CDR3 comprises SEQ ID NO: 224,

wherein the antigen binding site is specific for ROR1 and ROR2.

7. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-12, and wherein

the VH CDR1 comprises SEQ ID NO: 225,

the VH CDR2 comprises SEQ ID NO: 226,

the VH CDR3 comprises SEQ ID NO: 227,

the VL CDR1 comprises SEQ ID NO: 228,

the VL CDR2 comprises SEQ ID NO: 229, and

the VL CDR3 comprises SEQ ID NO: 230,

wherein the antigen binding site is specific for ROR1.

8. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-13, and wherein

the VH CDR1 comprises SEQ ID NO: 231,

the VH CDR2 comprises SEQ ID NO: 232,

the VH CDR3 comprises SEQ ID NO: 233,

the VL CDR1 comprises SEQ ID NO: 234,

the VL CDR2 comprises SEQ ID NO: 235, and

the VL CDR3 comprises SEQ ID NO: 236,

wherein the antigen binding site is specific for ROR1 and ROR2.

9. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-14, and wherein

the VH CDR1 comprises SEQ ID NO: 237,

the VH CDR2 comprises SEQ ID NO: 238,

the VH CDR3 comprises SEQ ID NO: 239,

the VL CDR1 comprises SEQ ID NO: 240,

the VL CDR2 comprises SEQ ID NO: 241, and

the VL CDR3 comprises SEQ ID NO: 242,

wherein the antigen binding site is specific for ROR1 and ROR2.

10. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-16, and wherein

the VH CDR1 comprises SEQ ID NO: 249,

the VH CDR2 comprises SEQ ID NO: 250,

the VH CDR3 comprises SEQ ID NO: 251,

the VL CDR1 comprises SEQ ID NO: 252,

the VL CDR2 comprises SEQ ID NO: 253, and

the VL CDR3 comprises SEQ ID NO: 254,

wherein the antigen binding site is specific for ROR1 and ROR2.

11. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding

site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-18, and wherein

the VH CDR1 comprises SEQ ID NO: 261,

the VH CDR2 comprises SEQ ID NO: 262,

the VH CDR3 comprises SEQ ID NO: 263

the VL CDR1 comprises SEQ ID NO: 264, and

the VL CDR2 comprises SEQ ID NO: 265,

wherein the antigen binding site is specific for ROR1 and ROR2.

12. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-19, and wherein

the VH CDR1 comprises SEQ ID NO: 266,

the VH CDR2 comprises SEQ ID NO: 267,

the VH CDR3 comprises SEQ ID NO: 268,

the VL CDR1 comprises SEQ ID NO: 269,

the VL CDR2 comprises SEQ ID NO: 270, and

the VL CDR3 comprises SEQ ID NO: 271,

wherein the antigen binding site is specific for ROR1 and ROR2.

13. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-20, and wherein

the VH CDR1 comprises SEQ ID NO: 272,

the VH CDR2 comprises SEQ ID NO: 273,

the VH CDR3 comprises SEQ ID NO: 274,

the VL CDR1 comprises SEQ ID NO: 275,

the VL CDR2 comprises SEQ ID NO: 276, and

the VL CDR3 comprises SEQ ID NO: 277,

wherein the antigen binding site is specific for ROR1.

14. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-22, and wherein

the VH CDR1 comprises SEQ ID NO: 284,

the VH CDR2 comprises SEQ ID NO: 285,

the VH CDR3 comprises SEQ ID NO: 286,

the VL CDR1 comprises SEQ ID NO: 287,

the VL CDR2 comprises SEQ ID NO: 288, and

the VL CDR3 comprises SEQ ID NO: 289,

wherein the antigen binding site is specific for ROR1 and ROR2.

15. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-24, and wherein

the VH CDR1 comprises SEQ ID NO: 296,

the VH CDR2 comprises SEQ ID NO: 297,

the VH CDR3 comprises SEQ ID NO: 298,

the VL CDR1 comprises SEQ ID NO: 299,

the VL CDR2 comprises SEQ ID NO: 300, and

the VL CDR3 comprises SEQ ID NO: 301,

wherein the antigen binding site is specific for ROR1 and ROR2.

16. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-25, and wherein

the VH CDR1 comprises SEQ ID NO: 302,

the VH CDR2 comprises SEQ ID NO: 303,

the VH CDR3 comprises SEQ ID NO: 304,

the VL CDR1 comprises SEQ ID NO: 305,

the VL CDR2 comprises SEQ ID NO: 306, and

the VL CDR3 comprises SEQ ID NO: 307,

wherein the antigen binding site is specific for ROR1.

17. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-26, and wherein

the VH CDR1 comprises SEQ ID NO: 308,

the VH CDR2 comprises SEQ ID NO: 309,

the VH CDR3 comprises SEQ ID NO: 310,

the VL CDR1 comprises SEQ ID NO: 311,

the VL CDR2 comprises SEQ ID NO: 312, and

the VL CDR3 comprises SEQ ID NO: 313,

wherein the antigen binding site is specific for ROR1.

18. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-30, and wherein

the VH CDR1 comprises SEQ ID NO: 332,
the VH CDR2 comprises SEQ ID NO: 333,
the VH CDR3 comprises SEQ ID NO: 334,
the VL CDR1 comprises SEQ ID NO: 335,
the VL CDR2 comprises SEQ ID NO: 336, and
the VL CDR3 comprises SEQ ID NO: 337,
wherein the antigen binding site is specific for ROR1.

19. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-32, and wherein

the VH CDR1 comprises SEQ ID NO: 344,
the VH CDR2 comprises SEQ ID NO: 345,
the VH CDR3 comprises SEQ ID NO: 346,
the VL CDR1 comprises SEQ ID NO: 347,
the VL CDR2 comprises SEQ ID NO: 348, and
the VL CDR3 comprises SEQ ID NO: 349,
wherein the antigen binding site is specific for ROR1.

20. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-33, and wherein

the VH CDR1 comprises SEQ ID NO: 350,

the VH CDR2 comprises SEQ ID NO: 351,

the VH CDR3 comprises SEQ ID NO: 352,

the VL CDR1 comprises SEQ ID NO: 353,

the VL CDR2 comprises SEQ ID NO: 354, and

the VL CDR3 comprises SEQ ID NO: 355,

wherein the antigen binding site is specific for ROR1.

21. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-34, and wherein

the VH CDR1 comprises SEQ ID NO: 356,

the VH CDR2 comprises SEQ ID NO: 357,

the VH CDR3 comprises SEQ ID NO: 358,

the VL CDR1 comprises SEQ ID NO: 359,

the VL CDR2 comprises SEQ ID NO: 360, and

the VL CDR3 comprises SEQ ID NO: 361,

wherein the antigen binding site is specific for ROR1 and ROR2.

22. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-36, and wherein

the VH CDR1 comprises SEQ ID NO: 368,

the VH CDR2 comprises SEQ ID NO: 369,

the VH CDR3 comprises SEQ ID NO: 370,

the VL CDR1 comprises SEQ ID NO: 371,

the VL CDR2 comprises SEQ ID NO: 372, and

the VL CDR3 comprises SEQ ID NO: 373,

wherein the antigen binding site is specific for ROR1 and ROR2.

23. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2A-37, and wherein

the VH CDR1 comprises SEQ ID NO: 374,

the VH CDR2 comprises SEQ ID NO: 375,

the VH CDR3 comprises SEQ ID NO: 376,

the VL CDR1 comprises SEQ ID NO: 377,
the VL CDR2 comprises SEQ ID NO: 378, and
the VL CDR3 comprises SEQ ID NO: 379,
wherein the antigen binding site is specific for ROR1.

24. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-1, and wherein

the VH CDR1 comprises SEQ ID NO: 385,
the VH CDR2 comprises SEQ ID NO: 386,
the VH CDR3 comprises SEQ ID NO: 387,
the VL CDR1 comprises SEQ ID NO: 388,
the VL CDR2 comprises SEQ ID NO: 389, and
the VL CDR3 comprises SEQ ID NO: 390,

wherein the antigen binding site is specific for ROR1 and ROR2.

25. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-2, and wherein

the VH CDR1 comprises SEQ ID NO: 391,

the VH CDR2 comprises SEQ ID NO: 392,

the VH CDR3 comprises SEQ ID NO: 393,

the VL CDR1 comprises SEQ ID NO: 394,

the VL CDR2 comprises SEQ ID NO: 395, and

the VL CDR3 comprises SEQ ID NO: 396,

wherein the antigen binding site is specific for ROR1 and ROR2.

26. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-3, and wherein

the VH CDR1 comprises SEQ ID NO: 397,

the VH CDR2 comprises SEQ ID NO: 398,

the VH CDR3 comprises SEQ ID NO: 399,

the VL CDR1 comprises SEQ ID NO: 400,

the VL CDR2 comprises SEQ ID NO: 401, and

the VL CDR3 comprises SEQ ID NO: 402,

wherein the antigen binding site is specific for ROR2.

27. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-4, and wherein

the VH CDR1 comprises SEQ ID NO: 403,

the VH CDR2 comprises SEQ ID NO: 404,

the VH CDR3 comprises SEQ ID NO: 405,

the VL CDR1 comprises SEQ ID NO: 406,

the VL CDR2 comprises SEQ ID NO: 407, and

the VL CDR3 comprises SEQ ID NO: 408,

wherein the antigen binding site is specific for ROR1 and ROR2.

28. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-5, and wherein

the VH CDR1 comprises SEQ ID NO: 409,

the VH CDR2 comprises SEQ ID NO: 410,

the VH CDR3 comprises SEQ ID NO: 411,

the VL CDR1 comprises SEQ ID NO: 412,

the VL CDR2 comprises SEQ ID NO: 413, and

the VL CDR3 comprises SEQ ID NO: 414,

wherein the antigen binding site is specific for ROR2.

29. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-6, and wherein

the VH CDR1 comprises SEQ ID NO: 415,

the VH CDR2 comprises SEQ ID NO: 416,

the VH CDR3 comprises SEQ ID NO: 417,

the VL CDR1 comprises SEQ ID NO: 418,

the VL CDR2 comprises SEQ ID NO: 419, and

the VL CDR3 comprises SEQ ID NO: 420,

wherein the antigen binding site is specific for ROR1 and ROR2.

30. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-7, and wherein

the VH CDR1 comprises SEQ ID NO: 421,

the VH CDR2 comprises SEQ ID NO: 422,

the VH CDR3 comprises SEQ ID NO: 423,

the VL CDR1 comprises SEQ ID NO: 424,
the VL CDR2 comprises SEQ ID NO: 425, and
the VL CDR3 comprises SEQ ID NO: 426,
wherein the antigen binding site is specific for ROR2.

31. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-8, and wherein

the VH CDR1 comprises SEQ ID NO: 427,
the VH CDR2 comprises SEQ ID NO: 428,
the VH CDR3 comprises SEQ ID NO: 429,
the VL CDR1 comprises SEQ ID NO: 430,
the VL CDR2 comprises SEQ ID NO: 431, and
the VL CDR3 comprises SEQ ID NO: 432,

wherein the antigen binding site is specific for ROR1 and ROR2.

32. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-9, and wherein

the VH CDR1 comprises SEQ ID NO: 433,

the VH CDR2 comprises SEQ ID NO: 434,

the VH CDR3 comprises SEQ ID NO: 435,

the VL CDR1 comprises SEQ ID NO: 436,

the VL CDR2 comprises SEQ ID NO: 437, and

the VL CDR3 comprises SEQ ID NO: 438,

wherein the antigen binding site is specific for ROR1 and ROR2.

33. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-10, and wherein

the VH CDR1 comprises SEQ ID NO: 439,

the VH CDR2 comprises SEQ ID NO: 440,

the VH CDR3 comprises SEQ ID NO: 441,

the VL CDR1 comprises SEQ ID NO: 442,

the VL CDR2 comprises SEQ ID NO: 443, and

the VL CDR3 comprises SEQ ID NO: 444,

wherein the antigen binding site is specific for ROR1 and ROR2.

34. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-11, and wherein

the VH CDR1 comprises SEQ ID NO: 445,

the VH CDR2 comprises SEQ ID NO: 446,

the VH CDR3 comprises SEQ ID NO: 447,

the VL CDR1 comprises SEQ ID NO: 448,

the VL CDR2 comprises SEQ ID NO: 449, and

the VL CDR3 comprises SEQ ID NO: 450,

wherein the antigen binding site is specific for ROR1 and ROR2.

35. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-12, and wherein

the VH CDR1 comprises SEQ ID NO: 451,

the VH CDR2 comprises SEQ ID NO: 452,

the VH CDR3 comprises SEQ ID NO: 453,

the VL CDR1 comprises SEQ ID NO: 454,

the VL CDR2 comprises SEQ ID NO: 455, and

the VL CDR3 comprises SEQ ID NO: 456,

wherein the antigen binding site is specific for ROR1 and ROR2.

36. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-13, and wherein

the VH CDR1 comprises SEQ ID NO: 457,

the VH CDR2 comprises SEQ ID NO: 458,

the VH CDR3 comprises SEQ ID NO: 459,

the VL CDR1 comprises SEQ ID NO: 460,

the VL CDR2 comprises SEQ ID NO: 461, and

the VL CDR3 comprises SEQ ID NO: 462,

wherein the antigen binding site is specific for ROR1 and ROR2.

37. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-14, and wherein

the VH CDR1 comprises SEQ ID NO: 463,

the VH CDR2 comprises SEQ ID NO: 464,

the VH CDR3 comprises SEQ ID NO: 465,

the VL CDR1 comprises SEQ ID NO: 466,

the VL CDR2 comprises SEQ ID NO: 467, and

the VL CDR3 comprises SEQ ID NO: 468,

wherein the antigen binding site is specific for ROR1 and ROR2.

38. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-15, and wherein

the VH CDR1 comprises SEQ ID NO: 469,

the VH CDR2 comprises SEQ ID NO: 470,

the VH CDR3 comprises SEQ ID NO: 471,

the VL CDR1 comprises SEQ ID NO: 472,

the VL CDR2 comprises SEQ ID NO: 473, and

the VL CDR3 comprises SEQ ID NO: 474,

wherein the antigen binding site is specific for ROR1 and ROR2.

39. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-16, and wherein

the VH CDR1 comprises SEQ ID NO: 475,

the VH CDR2 comprises SEQ ID NO: 476,

the VH CDR3 comprises SEQ ID NO: 477,

the VL CDR1 comprises SEQ ID NO: 478,

the VL CDR2 comprises SEQ ID NO: 479, and

the VL CDR3 comprises SEQ ID NO: 480,

wherein the antigen binding site is specific for ROR1 and ROR2.

40. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-17, and wherein

the VH CDR1 comprises SEQ ID NO: 481,

the VH CDR2 comprises SEQ ID NO: 482,

the VH CDR3 comprises SEQ ID NO: 483,

the VL CDR1 comprises SEQ ID NO: 484,

the VL CDR2 comprises SEQ ID NO: 485, and

the VL CDR3 comprises SEQ ID NO: 486,

wherein the antigen binding site is specific for ROR1 and ROR2.

41. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-18, and wherein

the VH CDR1 comprises SEQ ID NO: 487,

the VH CDR2 comprises SEQ ID NO: 488,

the VH CDR3 comprises SEQ ID NO: 489,

the VL CDR1 comprises SEQ ID NO: 490,

the VL CDR2 comprises SEQ ID NO: 491, and

the VL CDR3 comprises SEQ ID NO: 492,

wherein the antigen binding site is specific for ROR1 and ROR2.

42. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-19, and wherein

the VH CDR1 comprises SEQ ID NO: 493,

the VH CDR2 comprises SEQ ID NO: 494,

the VH CDR3 comprises SEQ ID NO: 495,

the VL CDR1 comprises SEQ ID NO: 496,

the VL CDR2 comprises SEQ ID NO: 497, and

the VL CDR3 comprises SEQ ID NO: 498,

wherein the antigen binding site is specific for ROR2.

43. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-20, and wherein

the VH CDR1 comprises SEQ ID NO: 499,

the VH CDR2 comprises SEQ ID NO: 500,

the VH CDR3 comprises SEQ ID NO: 501,

the VL CDR1 comprises SEQ ID NO: 502,

the VL CDR2 comprises SEQ ID NO: 503, and

the VL CDR3 comprises SEQ ID NO: 504,

wherein the antigen binding site is specific for ROR1 and ROR2.

44. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-21, and wherein

the VH CDR1 comprises SEQ ID NO: 505,

the VH CDR2 comprises SEQ ID NO: 506,

the VH CDR3 comprises SEQ ID NO: 507,

the VL CDR1 comprises SEQ ID NO: 508,
the VL CDR2 comprises SEQ ID NO: 509, and
the VL CDR3 comprises SEQ ID NO: 510,
wherein the antigen binding site is specific for ROR2.

45. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-22, and wherein

the VH CDR1 comprises SEQ ID NO: 511,
the VH CDR2 comprises SEQ ID NO: 512,
the VH CDR3 comprises SEQ ID NO: 513,
the VL CDR1 comprises SEQ ID NO: 514,
the VL CDR2 comprises SEQ ID NO: 515, and
the VL CDR3 comprises SEQ ID NO: 516,

wherein the antigen binding site is specific for ROR1 and ROR2.

46. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-23, and wherein

the VH CDR1 comprises SEQ ID NO: 517,

the VH CDR2 comprises SEQ ID NO: 518,

the VH CDR3 comprises SEQ ID NO: 519,

the VL CDR1 comprises SEQ ID NO: 520,

the VL CDR2 comprises SEQ ID NO: 521, and

the VL CDR3 comprises SEQ ID NO: 522,

wherein the antigen binding site is specific for ROR1 and ROR2.

47. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-24, and wherein

the VH CDR1 comprises SEQ ID NO: 523,

the VH CDR2 comprises SEQ ID NO: 524,

the VH CDR3 comprises SEQ ID NO: 525,

the VL CDR1 comprises SEQ ID NO: 526,

the VL CDR2 comprises SEQ ID NO: 527, and

the VL CDR3 comprises SEQ ID NO: 528,

wherein the antigen binding site is specific for ROR1 and ROR2.

48. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-25, and wherein

the VH CDR1 comprises SEQ ID NO: 529,

the VH CDR2 comprises SEQ ID NO: 530,

the VH CDR3 comprises SEQ ID NO: 531,

the VL CDR1 comprises SEQ ID NO: 532,

the VL CDR2 comprises SEQ ID NO: 533, and

the VL CDR3 comprises SEQ ID NO: 534,

wherein the antigen binding site is specific for ROR2.

49. A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising:

an antigen binding site specific for a ROR antigen, wherein the antigen binding site comprises an antibody VH region, and an antibody VL region, wherein the antigen binding site comprises all three VH region CDRs and all three VL region CDRs from the antibody designed I2C-26, and wherein

the VH CDR1 comprises SEQ ID NO: 535,

the VH CDR2 comprises SEQ ID NO: 536,

the VH CDR3 comprises SEQ ID NO: 537,

the VL CDR1 comprises SEQ ID NO: 538,

the VL CDR2 comprises SEQ ID NO: 539, and

the VL CDR3 comprises SEQ ID NO: 540,

wherein the antigen binding site is specific for ROR2.